Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET

Diana S Y Abdulla; Matthias Scheffler; Vanessa Brandes; Maximilian Ruge; Sabine Kunze; Sabine Merkelbach-Bruse; Lucia Nogova; Sebastian Michels; Rieke Fischer; Richard Riedel; Reinhard Büttner; Thorsten Persigehl; Stefan Grau; Norbert Galldiks; Alexander Drzezga; Carsten Kobe; Jürgen Wolf

doi:10.1016/j.cllc.2018.10.011

Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[¹⁸F]fluoroethyl)-L-tyrosine PET

Clin Lung Cancer. 2019 Mar;20(2):e148-e151. doi: 10.1016/j.cllc.2018.10.011. Epub 2018 Nov 5.

Authors

Diana S Y Abdulla¹, Matthias Scheffler¹, Vanessa Brandes¹, Maximilian Ruge², Sabine Kunze³, Sabine Merkelbach-Bruse⁴, Lucia Nogova¹, Sebastian Michels¹, Rieke Fischer¹, Richard Riedel¹, Reinhard Büttner⁴, Thorsten Persigehl⁵, Stefan Grau⁶, Norbert Galldiks⁷, Alexander Drzezga⁸, Carsten Kobe⁸, Jürgen Wolf⁹

Affiliations

¹ Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany.
² Center for Integrated Oncology Köln, Bonn, Germany; Department of Stereotaxy and Functional Neurosurgery, University Hospital of Cologne, Cologne, Germany.
³ Center for Integrated Oncology Köln, Bonn, Germany; Department of Radiotherapy, University Hospital of Cologne, Cologne, Germany.
⁴ Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany; Department of Pathology, University Hospital of Cologne, Cologne, Germany.
⁵ Center for Integrated Oncology Köln, Bonn, Germany; Department of Radiology, University Hospital of Cologne, Cologne, Germany.
⁶ Center for Integrated Oncology Köln, Bonn, Germany; Department of Neurosurgery, University Hospital of Cologne, Cologne, Germany.
⁷ Center for Integrated Oncology Köln, Bonn, Germany; Department of Neurology, University Hospital of Cologne, Cologne, Germany; Institute of Neuroscience and Medicine, Research Center Juelich, Juelich, Germany.
⁸ Center for Integrated Oncology Köln, Bonn, Germany; Department of Nuclear Medicine, University Hospital Cologne, Cologne, Germany.
⁹ Lung Cancer Group Cologne, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Köln, Bonn, Germany; Network Genomic Medicine (NGM) Lung Cancer, Cologne, Germany. Electronic address: juergen.wolf@uk-koeln.de.

PMID: 30528316
DOI: 10.1016/j.cllc.2018.10.011

No abstract available

Keywords: Brain metastases; EGFR-mutation; FET-PET; NSCLC; Therapy monitoring.

Publication types

Case Reports

MeSH terms

Adult
Antineoplastic Agents / therapeutic use*
Brain Neoplasms / diagnosis*
Brain Neoplasms / drug therapy
Brain Neoplasms / secondary
Carcinoma, Non-Small-Cell Lung / diagnosis*
Carcinoma, Non-Small-Cell Lung / drug therapy
Carcinoma, Non-Small-Cell Lung / secondary
ErbB Receptors / genetics
Erlotinib Hydrochloride / therapeutic use*
Female
Humans
Lung Neoplasms / diagnosis*
Lung Neoplasms / drug therapy
Lung Neoplasms / pathology
Mutation / genetics
Positron-Emission Tomography
Tyrosine / analogs & derivatives*

Substances

Antineoplastic Agents
(18F)fluoroethyltyrosine
Tyrosine
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors